TY - JOUR
T1 - Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer
AU - Chaput, N.
AU - Svrcek, M.
AU - Aupérin, A.
AU - Locher, C.
AU - Drusch, F.
AU - Malka, D.
AU - Taïeb, J.
AU - Goéré, D.
AU - Ducreux, M.
AU - Boige, V.
PY - 2013/8/20
Y1 - 2013/8/20
N2 - Background: The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II-III CRC patients. Methods: We constructed a tissue microarray from 196 consecutive patients with stage II-III CRC and compared CD3, CD4, CD8, CD57, CD68, CXCL9/MIG, CXCL13, and PPARγ immunoreactivity in tumour samples and their matched non-tumour tissue. We assessed their association with relapse-free survival (RFS; primary endpoint) and overall survival (OS) in multivariate Cox models. Results: Low densities of CD57+ and CD68+ tumour-infiltrating cells (TIC) independently predicted worse outcomes. A prognostic score combining CD57 (+, > vs-, ≤2 cells per spot) and CD68 (+, >0 vs-, =0 cells per spot) TIC density discriminated CRC patients at low (CD68+/CD57+), intermediate (CD68+/CD57-), or high (CD68-/CD57-) risk, with hazard ratios for the intermediate-risk and high-risk groups of 2.7 (95% confidence interval (CI): 1.3-5.8) and 9.0 (3.2-25.4) for RFS, and 2.5 (1.2-5.1) and 10.6 (3.8-29.2) for OS, respectively, as compared with the low-risk group. Corresponding 5-year survival rates (95% CI) in the low-, moderate-And high-risk groups were 84% (71-91), 65% (54-74), and 12% (2-47), respectively, for RFS, and 91% (80-96), 76% (66-84), and 25% (7-59), respectively, for OS. Conclusion: Tumour CD57+ and CD68+ TIC density assessment independently predicts survival in patients with stage II-III CRC. If validated, our score based on a quick, inexpensive, and well-established method such as point counting on diagnostic tissue sections could be used routinely as a prognostic tool in CRC patients.
AB - Background: The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II-III CRC patients. Methods: We constructed a tissue microarray from 196 consecutive patients with stage II-III CRC and compared CD3, CD4, CD8, CD57, CD68, CXCL9/MIG, CXCL13, and PPARγ immunoreactivity in tumour samples and their matched non-tumour tissue. We assessed their association with relapse-free survival (RFS; primary endpoint) and overall survival (OS) in multivariate Cox models. Results: Low densities of CD57+ and CD68+ tumour-infiltrating cells (TIC) independently predicted worse outcomes. A prognostic score combining CD57 (+, > vs-, ≤2 cells per spot) and CD68 (+, >0 vs-, =0 cells per spot) TIC density discriminated CRC patients at low (CD68+/CD57+), intermediate (CD68+/CD57-), or high (CD68-/CD57-) risk, with hazard ratios for the intermediate-risk and high-risk groups of 2.7 (95% confidence interval (CI): 1.3-5.8) and 9.0 (3.2-25.4) for RFS, and 2.5 (1.2-5.1) and 10.6 (3.8-29.2) for OS, respectively, as compared with the low-risk group. Corresponding 5-year survival rates (95% CI) in the low-, moderate-And high-risk groups were 84% (71-91), 65% (54-74), and 12% (2-47), respectively, for RFS, and 91% (80-96), 76% (66-84), and 25% (7-59), respectively, for OS. Conclusion: Tumour CD57+ and CD68+ TIC density assessment independently predicts survival in patients with stage II-III CRC. If validated, our score based on a quick, inexpensive, and well-established method such as point counting on diagnostic tissue sections could be used routinely as a prognostic tool in CRC patients.
UR - http://www.scopus.com/inward/record.url?scp=84883183628&partnerID=8YFLogxK
U2 - 10.1038/bjc.2013.362
DO - 10.1038/bjc.2013.362
M3 - Article
C2 - 23868006
AN - SCOPUS:84883183628
SN - 0007-0920
VL - 109
SP - 1013
EP - 1022
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 4
ER -